Russia could launch the corona vaccine in less than two weeks despite the safety. The vaccine will be vector-based and will be launched by the Moscow-based Gamaleya Institute. The Russian officials made it clear that they are going to launch the vaccine by the end of the second week of August.
“It’s a sputnik moment, Americans were surprised when they heard Sputnik beeping. It’s the same with this vaccine. Russia will have got there first. Russia marshaled its leadership position in vaccine development and proven its Ebola and MERS vaccine platform to bring the first safe and efficient solution to the world’s biggest problem,” said Kirill Drimitive CEO of the Russian Direct Investment Fund to CNN
Over the fact, Russia is still to release the scientific data on this vaccine trial. According to the media reports, the country’s push for the vaccine came after the disturbed political from the Kremlin. If the vaccine succeeds then Russia may surpass America and emerge as a global force in terms of medical science.
The human trials of the vaccine which is still incomplete, so this is the biggest reason to worry. At this stage, thousands of vaccine trials are on the process around the world but very few of them have reached the large efficacy trials and some vaccines are also in the third phase of the trails.
The vaccine is still left to complete the second phase trials
The Russians are still to complete the second phase of this COVID-19 vaccine but the producers are planning to launch it before the second week of August.
The Russian news agency Interfax also reported, quoted by Health Minister Mikhail Murashko, “Russia will allow the widespread use of the vaccine parallel to the phase 3 trials. Next month health care workers will be at high risks for the COVID-19, so before the final stage of the clinical trials, the medics will be allowed to use the vaccine.”
“The individuals at higher risk of getting infected with the coronavirus such as older people and the people who are at the stake of their health condition will also be prioritized for the vaccine,” Mikhail Murashko said to Interfax.
Around 800 peoples will be hand-picked for the phase 3 trials which will also include the Russian soldiers as the volunteers.
This particular vaccine uses human adenovirus vectors which are much weaker than the others to stop the replication in the body. Patients will be given a double booster shot to fulfill the two vector-based criteria for the vaccine.
